1Chekman, IS, 2Belenichev, IF, 2Demchenko, AV, 3Bobrova, VI, 1Kucherenko, LI, 2Gorchakova, NA, 2Bukhtiyarova, NV
1O.O. Bogomolets National Medical University, Kyiv
2Zaporizhia State Medical University, Zaporizhia
3P.L. Shupyk National Medical Academy of Postgraduate Education, Kyiv
Sci. innov. 2014, 10(4):56-68
https://doi.org/10.15407/scine10.04.056
Section: The World of Innovations
Language: English
Abstract: 

The clinical and pharmacological characteristics of nootropics as one of the most effective groups of neuropsychotropic drugs have been considered. The nootropics has been classified by the principal mechanism of action. The examples of clinical use of drugs on patients with chronic cerebral ischemia have been given.

Keywords: cerebrovascular diseases, cognitive disorders, neuroprotection, nootropics
References: 

1. Luschyk, U.B. and Alekseeva, T.S.: Why Do Mortality and Disease Incidence Related to Cardiovascular Pathology Not Decline? Practical Angiology, 3 (32), 5—11 (2010) (in Ukrainian).
2. Mischenko, T.S.: Epidemiology of Neurological Diseases in Ukraine. NeuroNEWS, 3, 76—77 (2008) (in Ukrainian).
3. Hacke W., Kaste, M., Skyhoi Olsen, T. et al.: Acute Treatment of Ischemic Stroke.Cerebrovascular Diseases, 10, 1—11 (2000).
https://doi.org/10.1159/000047578
4. Netiazhenko, V. and Malchevska, T.: Anti-Thrombocyte Strategy of Primary and Secondary Prevention of Cardiovascular Accidents (Based on Materials of Consensus on Use of Anti-Thrombocyte Drugs). Medicines of Ukraine, 6, 13—20 (2004) (in Ukrainian).
5. Zozulia I.S. and Zozulia, A.I.: Epidemiology of Cerebrovascular Diseases in Ukraine. Ukrainian Medical Journal, 5 (85), 38—41 (2011) (in Ukrainian).
6. Moroz, V.A.: Discirculatory Encephalopathy: Modern Approach to Treatment and Prevention. Pharmacist. 9, 20—23 (2008) (in Ukrainian).
7. Mischenko, T.S., Zdesenko, I.V., Linskaya, A.V., and Mischenko, V.N.: New Targets of Therapy in Patients with Chronic Cerebral Ischemia. International Neurological Journal, (40), 7—17 (2011) (in Russian).
8. Schmidt, E.V.: Classification of Vascular Affections of Brain and Spinal Cord. Journal of Neurology and Psychiatry, 9, 1281—1288 (1985) (in Russian).
9. Damulin, I.V., Parfenov, V.A., Skoromets, A.A., and Uakhno, N.N. (2003). Blood Circulation Failure in Brain
and Spinal Cord. In Yakhno, N.N. (ed.), Neural System Disorders: Manual for Therapists. Moscow: Medicine, 231—302 (in Russian).
10. Levin, O.S.: Modern Approaches to Diagnostics and Treatment of Discirculatory Encephalopathy. International Neurological Journal, 1(47), 117—124 (2012) (in Russian).
11. Pantoni L., Poggesi A., and Inzitari D.: The Relation between White Matter Lesions and Cognition. Curr. Opin. Neurol. 20, 390—397 (2007).
https://doi.org/10.1097/WCO.0b013e328172d661
12. Roman, G.C., Erkinjuntti, T., Wallin, A. et al.: Subcortical Ischemic Vascular Dementia. Lancet Neurology, 1, 426—436 (2002).
https://doi.org/10.1016/S1474-4422(02)00190-4
13. Zakharov, V.V. and Yakhno, N.N.: Treatment of Mild and Moderate Cognitive Disorders. Russian Medical Journal, 10, 797—801 (2007) (in Russian).
14. Yakhno, N.N.: Cognitive Disorders in Neurological Clinical Picture. Neurological Journal, II (Annex 1), 4—13 (2006) (in Russian).
15. Bowler, J.V.: Vascular Cognitive Impairment. J. Neurol. Neurosurg. Psychiatry, 76 (Suppl. V), 35—44 (2005).
https://doi.org/10.1136/jnnp.2005.082313
16. De Haan, E.H., Nys, G.M., and Van Zandvoort, M.J.V.: Cognitive Function Following Stroke and Vascular Cognitive Impairment. Curr. Opin. Neurol, 19, 559—564 (2006).
https://doi.org/10.1097/01.wco.0000247612.21235.d9
17. Yavorskaya, V.A., Flomin Yu.V., and Grebeniuk, A.V.: Approaches to the Study of Cognitive Functions at Cerebrovascular Diseases and Other Cerebral Organic Affections: Survey of Foreign Publications. International Neurological Journal, 2 (18), 131—137 (2008) (in Russian).
18. Lovenstone, S. and Gauthier, S. (2001). Management of Dementia. London: Martin Dunitz.
19. Hodges, J.R.: Cognitive Assessment for Clinicians. J. Neurol. Neurosurg. Psychiatry, 76, 22—30 (2005).
https://doi.org/10.1136/jnnp.2004.059758
20. Belenichev, I.F., Chernyi, V.I., and Kolesnik, Yu.M. (2009). Rational Neuroprotection. Donetsk: Zaslavskii Publishing House (in Russian).
21. Gusev, E.I. and Skvortsova, V.I. (2001). Cerebral Ischemia. Moscow: Medicine (in Russian).
22. Vereschagin, N.V., Morgunov V.A., and Gulevskaia, T.S. (1997). Cerebral Pathology at Arthrosclerosis and Arterial Hypertension. Moscow: Medicine (in Russian).
23. Yakhno, N.N., Levin, O.S., and Damulin, I.V.: Comparison of the Clinical and the MRT Data in the Treatment of Discirculatory Encephalopathy. Report 2: Cognitive Disorders. Neurological Journal, 6, 3, 10—19 (2001) (in Russian).
24. Belenichev, I.F., Mazur, I.A., and Stets, V.R.: Nootropic Therapy: the Past, the Present, and the Future. News of Medical Science and Pharmacology, 15 (155), 10 (2004) (in Russian).
25. Burchinskii, S.G.: Prospects for Nootropic Drugs for Treatment of Discirculatory Encephalopathy. Journal of Practitioner, 2, 51—55 (2005) (in Russian).
26. Suslina, Z.A., Maksimova, M.Yu., and Fedorova, T.N.: Chronic Cerebrovascular Diseases: Clinical and Antioxidative Efficacy of Mildronate. The Therapist, 4, 44—48 (2007) (in Russian).
27. Chernii, V.I., Kolesnikov, A.N., and Gorodnik, G.A. (2007). Cerebral Ischemia in Medical Science of Critical Conditions. Neuroprotection (Pathophysiology, Terminology, and Properties of Drugs): Methodical Recommendations (Manuscript copyright). Kyiv (in Russian).
28. Gusev, E.I., Skvortsova, V.I., and Platonova, I.A.: Ischemic Stroke Therapy. Consilium Medicum, 5, 8, 21— 29 (2003) (in Russian).
29. Suslina, Z.A., Fedorova, T.N., and Maksimova, M.Yu.: Antioxidant Therapy for the Treatment of Ischemic Stroke. Journal of Neurology and Psychiatry, 100, 10, 34—38 (2000) (in Russian).
30. Ciani, E.: Inhibition of Free Radical Production or Free Radical Scavenging Protects from the Excitotoxic Cell Death Mediated by Glutamate in Cultures of Cerebellar Granule Neurons. Brain Res. 728, 11, 1—6 (1996).
https://doi.org/10.1016/0006-8993(96)00382-4
31. Chekman, I.S., Gorchakova, N.A., Kazak, L.I, et al. (2013). Pharmacology: Manual for HEE Students. Vinnytsia: Nova Knyha (in Russian).
32. Chernii, V.I., Kalmykova, T.N., and Chernii, E.V. (2008). Intensive Therapy of Critical Condition Caused by Cerebral Stroke: Methodical Recommendations (Manuscript copyright). Kyiv (in Russian).
33. Aleksandrov, Yu.I., Grechenko, T.N., and Gavrilov, V.V.: Regularities of Formation and Implementation of Individual Experience. Journal of Higher Nervous Activity, 1, 2, 34—45 (1997) (in Russian).
34. Adibhafla, R.M. and Hatcher, J.F.: Citidine 5-Diphosphocholine (CDP-Choline) Insfroke and Ofher CNS Disorders. Neurochemical Research, 30, 15—23 (2005).
https://doi.org/10.1007/s11064-004-9681-8
35. Adibhatla, R.M. and Hatcher, J.F.: Citicoline Mechanismus and Clinical Efficacy in Cerebral Ischemia. J. of Neuroscience Research, 70, 133—139 (2002).
https://doi.org/10.1002/jnr.10403
36. Levin, O.S.: Use of Citicoline for the Treatment of Stroke. Russian Medical Journal, 26, 1772—1777 (2008) (in Russian).
37. Skvortsova, V.I. and Boitsova, A.: Neuroprotective Citicoline Therapy in the Acute Period of Ischemic Stroke. The Therapist, 12, 25—28 (2007) (in Russian).
38. Adibhatla, R.M., Hatcher, J.F., and Dempsey, R.I.: Citicoline: Neuroprotective Mechanisms in Cerebral Ischemia. J.Nerocuem., 80, 12—13 (2002).
39. Cobo, E., Secades, J.J., Miras, F. et al.: Boosting the Chances to Improve Stroke Treatment. Stroke, 41, 143—150 (2010).
https://doi.org/10.1161/STROKEAHA.109.567404
40. Saver, J.L.: Citicoline: Update on a Promising and Widely Available Agent for Neuroprotection and Neurorepair. Rev. Neurol. Dis., 5, 167—177 (2008).
41. Fioravanti, M., Buckley, A.E., and Agnoli, A. (1982). Citicoline in CCVD Patients: Preliminary Results of a Multicenter Study. Cerebral Pathology in Old Age: Neuroradiological and Neurophysiological Correlations. Pavia.
42. Agnoli, A., Fioravanti, M., Lechner, H., and Zappia V. (1985). Efficacy of CDPcholine in Chronic Cerebral Vascular Diseases (CCV). In: Novel Biochemical, Pharmacological and Clinical Aspects of Cytidinediphosphocholine. Amsterdam: Elsevier, 305—315.
43. Chandra, B.: Treatment of Multi-Infarct Dementia with Citicoline. J Stroke Cerebrovasc Dis., 2, 232—233 (1992).
https://doi.org/10.1016/S1052-3057(10)80055-2
44. Capurso, A., Capurso, S., Panza, F. et al.: Efficacy of Cytidine Diphosphate Choline in Patients Affected by Chronic Cerebrovascular Disease. Clin Drug Invest., 12, 26—38 (1996).
https://doi.org/10.2165/00044011-199612010-00004
45. Tanaka, Y., Minematsu, K., Hirano, T. et al.: Effects of CDPcholine on Dynamic Changes in LCBF and Cognitive Function in Demented Subjects-PET Study. Rinsho Shinkeigaku, 34, 877—881 (1994).
46. Cacabelos, R., Alvarez, X.A., Franco, A. et al.: Therapeutic Effects of CDPcholine in Alzheimer’s Disease and Multiinfarct Dementia. Ann Psychiat., 3, 233—245 (1992).
47. Amenta, F., Di Tullio, M.A., and Tomassoni, D.: The Cholinergic Approach for the Treatment of Vascular Dementia: Evidence from Pre-Clinical and Clinical Studies. Clin Exp Hypertens., 24, (2002).
48. Fioravanti, M. and Yanagi, M.: Cytidinediphosphocholine (CDPcho line) for Cognitive and Behavioural Disturbances Associated with Chronic Cerebral Disorders in the Elderly. The Cochrane Database of Systematic Reviews, 3 (2009).
49. Blvarez-Sabhn, J., Ortega, G., Jacas, C. et al.: Citicoline Treatment Prevents Neurocognitive Decline after a First Ischemic Stroke. Cerebrovasc. Dis., 29 (Suppl. 2), 268 (2010).
50. Secades, J. and Lorenzo, J.: Citicoline. Pharmacol Clin Rev., 27 (Suppl. B), 1—56 (2006).
51. Renshaw, P.F., Babb, S.M., Yurgelun-Todd, D.A. et al.: Chronic Citicholine (CDP-choline administration Alters Brain Phospholipid Metabolites and Improves Cognitive Performance in Healthy, Older Adults. 37th ACNP Annual Meeting: Puerto Rico, (1998).
52. Fioravanti, M. and Yanagi, M.: Cytidinediphosphocholine (CDP-choline) for Cognitive and Behavioural Disturbances Associated with Chronic Cerebral Disorders in the Elderly. Cochrane Database Syst. Rev., 18, CD000269 (2005).
53. Fioravanti, M. and Buckley, A.E.: Citicoline (Cognizin) in the Treatment of Cognitive Impairment. Clin. Interv. Aging, 1, 247—251 (2006).
https://doi.org/10.2147/ciia.2006.1.3.247
54. Mazza, M., Capuano, A., Bria, P., and Mazza S.: Ginkgo Biloba and Doneperesil: a Comparison in the Treatment of Alzheimer’s Dementia in a Randomized Placebo-Controlled Double-Blind Study. Eur. J. Neurol., 13, 9, 981—85 (2006).
https://doi.org/10.1111/j.1468-1331.2006.01409.x
55. Mazur, I.A., Belenichev, I.F., and Kucherenko, L.I.: Patent of Russian Federation no. 2248203, appl. No. 2003104538/15 of 14.02.2003 (in Russian).
56. Dziak, L.A. and Golik, V.A.: Efficacy of Thiocetam for the Treatment of Discirculatory Encephalopathy Caused by Atherosclerotic Disease of Cerebral Arteries. News of Medical Science and Pharmacology, 10-11, 4—5 (2004) (in Russian).
57. Kuznetsova, S.M., Kuznetsov, V.V., and Vorobei, V.M.: Thiocetam Effect on Functional Condition of Patients Who Have Suffered Stroke. International Neurological Journal, 1, 45—51 (2005) (in Russian).
58. Dziak, L.A., Miziakina, E.V., and Pavlov, A.I.: Post Traumatic Mnestic Disorders. International Neurological Journal, 8 (46), 11—19 (2011) (in Russian).